Core Insights - The company reported a revenue of 2.795 billion yuan, a year-on-year decrease of 6.72% [1] - Net profit was 78.63 million yuan, down 46.95% year-on-year, primarily due to the impact of expanded centralized procurement on traditional Chinese medicine formula granules and intensified industry competition leading to price pressure [1] Revenue Breakdown - Revenue from traditional Chinese medicine formula granules and decoction pieces was 1.232 billion yuan, a year-on-year decline of 5.75% [1] - Revenue from the core product, Xuebijing injection, was 466 million yuan, a slight increase of 2.88% year-on-year [1] - The smart supply chain for medical devices generated revenue of 433 million yuan, down 3.92% year-on-year [1] Profitability and Loss Provisions - The gross profit margin for all segments declined, with the smart supply chain for medical devices experiencing a significant drop of 16.85% [1] - The company recognized an asset impairment loss of 30.495 million yuan, mainly for inventory write-downs related to raw materials and inventory products older than 24 months [1] - Accounts receivable bad debt losses amounted to 6.5879 million yuan, indicating pressure on cash collection [1]

Group 1 - The company did not distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [2] - There were no changes in the controlling shareholder or actual controller during the reporting period [3] - The company has no preferred shareholders or related holdings to report for the current period [3] Group 2 - The company does not require retrospective adjustments or restatements of previous accounting data [2] - There are no significant matters reported during the period [3]

Group 1 - The stock price of Hongri Pharmaceutical is reported at 4.06 yuan, down 0.18 yuan or 4.25% from the previous trading day, with a trading volume of 1.007 million hands and a transaction amount of 419 million yuan [1] - For the first half of 2025, the company achieved an operating income of 2.795 billion yuan, a year-on-year decrease of 6.72%, and a net profit attributable to shareholders of 78.63 million yuan, down 46.95% year-on-year [1] - The net cash flow from operating activities was 384 million yuan, an increase of 8.12% year-on-year [1] Group 2 - The company announced that there are currently no overdue external guarantees and stated its commitment to continuously optimize governance and internal control to enhance operational efficiency and competitiveness [1] - As of the end of the first half of 2025, Chengdu Xingcheng Investment Group Co., Ltd. holds the highest shareholding ratio among the top ten circulating shareholders at 22.24% [1]

证券日报网讯8月27日晚间，红日药业（300026）发布公告称，公司及子公司无逾期对外担保情况，亦 无为股东、实际控制人及其关联方提供担保的情况。 ...

Group 1 - The company emphasizes that returning value to shareholders is a consistent principle of its governance [2] - The company plans to continuously optimize governance and internal controls to enhance operational efficiency and competitiveness [2] - The company aims to strengthen communication with investors and strictly adhere to all legal regulations applicable to listed companies [2]

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-046 天津红日药业股份有限公司 关于 2025 年度公司、子公司及孙公司 向银行等金融机构申请综合授信及担保事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 截至本公告披露日，公司、子公司及孙公司累计提供担保总额（含本次担保） 为人民币 132,660.00 万元，占公司最近一期经审计净资产的 15.35%。本次担保 事项均为公司及公司合并报表范围内的子公司及孙公司提供的担保，部分子公司 及孙公司资产负债率超过 70%，但担保金额未超过公司最近一期经审计净资产 50%的情形，请投资者充分关注担保风险。 天津红日药业股份有限公司（以下简称"公司"）于2025年08月26日召开了 第九届董事会第二次会议，审议通过了《关于2025年度公司、子公司及孙公司向 银行等金融机构申请综合授信及担保事项的议案》。议案已经公司独立董事专门 会议审议通过，该事项尚需提交公司股东大会审议批准。现将相关情况公告如下： 一、申请银行综合授信情况 为满足公司、子公司及孙公司日 ...

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-045 天津红日药业股份有限公司 关于公司 2025 年半年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 （一）本次计提资产减值准备的原因 为真实反映公司的财务状况和资产价值，依据《企业会计准则》及公司会计 政策的相关规定，公司及子公司于 2025 年 6 月 30 日对应收款项、存货等各类资 产进行了检查，并对存在可能发生减值迹象的金融资产在整个存续期内的预期信 用损失、各类存货的可变现净值进行了分析和评估，在此基础上对发生资产减值 损失的资产计提减值准备。经测算，2025 年上半年公司计提减值损失合计 37,083,154.76 元，具体情况如下： （二）本次计提资产减值损失的范围和金额 （三）本次计提资产减值准备的情况说明 1 单位：元 项目 2025 年上半年计提金额 信用减值损失 6,587,868.94 其中：应收票据坏账损失 35,697.47 应收账款坏账损失 2,220,219.23 其他应收款坏账损失 4,331,952.2 ...

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-044 天津红日药业股份有限公司 关于公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司募集资金监管规则》（证监会公告 [2025]10 号）和《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》《深圳证券交易所创业板上市公司自律监管指南第 2 号——公 告格式第 21 号：上市公司募集资金年度存放、管理与使用情况的专项报告格式 等有关规定，天津红日药业股份有限公司（以下简称"公司"或"本公司"）董 事会编制了 2025 年半年度募集资金存放与实际使用情况的专项报告，具体情况 如下： 一、募集资金基本情况 （一）募集资金金额及到位时间 经中国证券监督管理委员会《关于核准天津红日药业股份有限公司首次公开 发行股票并在创业板上市的批复》（证监许可[2009]1038 号）核准，并经深圳证 券交易所同意，本公司由主承销商国都证券有限责任公司（以下简称"国都证券"） ...

天津红日药业股份有限公司 天津红日药业股份有限公司 第九届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津红日药业股份有限公司（以下简称"公司"）第九届监事会第二次会议 于 2025 年 08 月 26 日在天津市武清开发区创业总部基地 B01 号楼公司会议室以 现场加通讯表决方式召开,会议通知于 2025 年 08 月 15 日以邮件、电话的方式发 出。会议应参加监事 3 人，实际参加会议的监事 3 人（其中以通讯表决方式出席 会议的监事为 2 人）。本次会议以通讯表决的监事分别为：监事会主席叶尚书女 士、监事李俊先生。公司部分高级管理人员列席了会议。本次会议召开符合《公 司法》等相关法律法规和《公司章程》《公司监事会议事规则》的有关规定。 会议由公司监事会主席叶尚书女士主持，参会监事投票表决通过如下议案： 一、审议通过《关于公司<2025 年半年度报告>及其摘要的议案》； 监事会认为：公司董事会编制及审议公司《2025 年半年度报告》及摘要的 程序符合法律、行政法规和中国证监会的规定，公司《2025 年半年度报告》及 摘要真实 ...

Core Viewpoint - Hongri Pharmaceutical (300026.SZ) reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was 2.795 billion yuan, a year-on-year decrease of 6.72% [1] - The net profit attributable to shareholders of the listed company was 78.63 million yuan, reflecting a year-on-year decrease of 46.95% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 69.18 million yuan, down 49.53% year-on-year [1] - Basic earnings per share were reported at 0.03 yuan [1]